Investment case

Novo Nordisk A/S

NVO · 43 developments mapped · last assessed 2026-09-28

Market Ontology has mapped 43 macro, policy, and market developments to Novo Nordisk A/S since 2026-08-18. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

Last close

Unavailable

No published quote

Market cap

Unavailable

Equity value

Diluted shares

Unavailable

Latest reported

Sector

Unavailable

Listing

Unavailable

Filings

Unavailable

No published filing

Valuation

No validated run has been published for NVO yet, so no modelled value is shown. The NVO valuation is in the public catch-up queue.

Subscribers do not wait for the weekly cycle: they run NVO on demand, against live prices and the latest filings, and change any assumption the developments below move.

Filed financials

A validated filed-statement snapshot has not been published for NVO. Missing data is not estimated or replaced with scenario assumptions.

Continue this research

Value NVO on your own assumptions

Run the valuation on Novo Nordisk A/S, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run NVO on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade NVO

Professional

Open trade discovery with Novo Nordisk A/S and NVO already in context.

Open

Find pricing gaps in NVO

Institutional

Open relative-value and arbitrage analysis with NVO already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens NVO first, then any listed company you want to value or monitor.

Choose another company

Current case

Strongest support
Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli Lilly
Direct product launch and market expansion. Oral formulation addresses supply constraints and expands patient access, potentially increasing sales volume.
2026-09-23 · Moves market share growth in glp 1 segment, increased total addressable market (tam) due to oral formulation, potential for improved pricing power in certain segments
Main threat
NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across Doses
Increased competition from lower-cost compounded alternatives for GLP-1 drugs, potentially impacting market share and pricing power for branded products.
2026-09-01 · Moves future sales growth of glp 1 portfolio, average selling price (asp) of glp 1 drugs, market share projections
Open question
Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage
Increased competitive pressure in the GLP-1 market, particularly from oral formulations and broader PBM coverage for rival products.
2026-09-18 · Moves market share projections, pricing, r&d investment needs

What changed, by assumption

Market share growth in glp 1 segment

2026-09-23Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli Lilly
2026-08-30Novo Nordisk Introduces Wegovy Pill and Partners on Long-Acting Implant
2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Delivery Partnership

Market share growth in obesity

2026-09-23Novo Rebrands to 'Novo' and Launches Oral GLP-1 Pill in Obesity Market Push

Market share growth in obesity/diabetes

2026-09-23Novo Rebrands to 'Novo' and Deploys Oral GLP-1 Pill in Market Share Defense
2026-08-30Novo Nordisk Launches Oral Wegovy and Partners with Vivani for GLP-1 Implants

Future sales growth of glp 1 portfolio

2026-09-01NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across Doses

Future revenue growth rates for glp 1 products

2026-08-31Novo Nordisk Advances Oral Wegovy and Implant Program Against Eli Lilly Lead

Event impact log

Full ledger →

Date	Mechanism	Direction	Horizon	Impact
2026-09-28	Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocation	watch	3-12m	0.30
2026-09-28	Eli Lilly discontinues pipeline GLP-1 candidate following efficacy review	Bullish	1-3m	0.20
2026-09-28	Eli Lilly Discontinues Experimental GLP-1 Candidate Following Efficacy Review	mixed	1-3m	0.30
2026-09-28	Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise lead	Bullish	1-3m	0.30
2026-09-28	Eli Lilly Discontinues Early-Stage GLP-1 Candidate Following Efficacy Review	Bullish	1-3m	0.20
2026-09-28	Eli Lilly Drops Experimental GLP-1 Candidate as Core Incretin Portfolio Reaches 65% of Sales	Bullish	1-3m	0.40
2026-09-28	Eli Lilly Discontinues Sub-Par GLP-1 Candidate to Refocus Capital on Next-Gen Formulations	mixed	3-12m	0.40
2026-09-28	Eli Lilly Drops Experimental GLP-1 Candidate Following Subpar Efficacy Data	Bullish	1-3m	0.50
2026-09-27	Eli Lilly Drops Experimental Obesity Candidate; Incretins Exceed 65% of Total Revenue	Bullish	1-3m	0.40
2026-09-27	Eli Lilly Drops Pipeline Obesity Asset as GLP-1 Franchise Exceeds 65% Revenue	Bullish	3-12m	0.40
2026-09-27	Eli Lilly discontinues developmental obesity drug over unmet efficacy threshold	Bullish	1-3m	0.40
2026-09-27	Eli Lilly Drops Experimental Obesity Candidate While Core GLP-1s Exceed 65% of Revenue	mixed	1-3m	0.40

Value NVO yourself$399/month

Continue this research

Value NVO on your own assumptions

Run the valuation on Novo Nordisk A/S, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run NVO on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade NVO

Professional

Open trade discovery with Novo Nordisk A/S and NVO already in context.

Open

Find pricing gaps in NVO

Institutional

Open relative-value and arbitrage analysis with NVO already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens NVO first, then any listed company you want to value or monitor.

Choose another company

Novo Nordisk A/S

NVO · 43 developments mapped · last assessed 2026-09-28

Value NVO on your own assumptions

Run the valuation on Novo Nordisk A/S, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run NVO on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade NVO

Professional

Open trade discovery with Novo Nordisk A/S and NVO already in context.

Open

Find pricing gaps in NVO

Institutional

Open relative-value and arbitrage analysis with NVO already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens NVO first, then any listed company you want to value or monitor.

Choose another company

Date

Mechanism

Direction

Horizon

Impact

2026-09-28

Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocation

watch

3-12m

0.30

2026-09-28

Eli Lilly discontinues pipeline GLP-1 candidate following efficacy review

Bullish

1-3m

0.20

2026-09-28

Eli Lilly Discontinues Experimental GLP-1 Candidate Following Efficacy Review

mixed

1-3m

0.30

2026-09-28

Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise lead

Bullish

1-3m

0.30

2026-09-28

Eli Lilly Discontinues Early-Stage GLP-1 Candidate Following Efficacy Review

Bullish

1-3m

0.20

2026-09-28

Eli Lilly Drops Experimental GLP-1 Candidate as Core Incretin Portfolio Reaches 65% of Sales

Bullish

1-3m

0.40

2026-09-28

Eli Lilly Discontinues Sub-Par GLP-1 Candidate to Refocus Capital on Next-Gen Formulations

mixed

3-12m

0.40

2026-09-28

Eli Lilly Drops Experimental GLP-1 Candidate Following Subpar Efficacy Data

Bullish

1-3m

0.50

2026-09-27

Eli Lilly Drops Experimental Obesity Candidate; Incretins Exceed 65% of Total Revenue

Bullish

1-3m

0.40

2026-09-27

Eli Lilly Drops Pipeline Obesity Asset as GLP-1 Franchise Exceeds 65% Revenue

Bullish

3-12m

0.40

2026-09-27

Eli Lilly discontinues developmental obesity drug over unmet efficacy threshold

Bullish

1-3m

0.40

2026-09-27

Eli Lilly Drops Experimental Obesity Candidate While Core GLP-1s Exceed 65% of Revenue

mixed

1-3m

0.40

Value NVO on your own assumptions

Run the valuation on Novo Nordisk A/S, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run NVO on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade NVO

Professional

Open trade discovery with Novo Nordisk A/S and NVO already in context.

Open

Find pricing gaps in NVO

Institutional

Open relative-value and arbitrage analysis with NVO already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens NVO first, then any listed company you want to value or monitor.

Choose another company